TScan Therapeutics (TCRX)
(Delayed Data from NSDQ)
$8.01 USD
+0.28 (3.62%)
Updated May 13, 2024 04:00 PM ET
After-Market: $8.01 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Brokerage Reports
TScan Therapeutics, Inc. [TCRX]
Reports for Purchase
Showing records 1 - 20 ( 34 total )
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE- ASGCT 2024 Abstract Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Multiple Heme/Solid Tumor Data Throughout 2024; Reit Buy and $15 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Batter Up; T-plex at the Plate, TSC-100/101 on Deck.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
TSC-100/TSC-101 Displays Impressive Relapse-Free Levels (100%) with Complete Donor Chimerism
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
TSC-100/101 Data at ASH 23 Continue to Trend Positive
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
TSC-100/101 Data at ASH23 in Heme Malignancies Remains Key Catalyst; Reit. Buy and $15 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ASH 2023 Abstract Round Up for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
EORTC-NCI-AACR 2023: Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
UntitledTCR-Ts Continue Assault on Heme/Solid Tumors; Reit. Buy and $15 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A